Molecular Diagnostics Industry Leader Joins Portable Cannabis Analyzer Company
MyDx, the creator of the first multi-use handheld chemical analyzer designed for cannabis professionals and retail consumers to understand the chemical profile of cannabis, has announced that Heiner Dreismann, Ph.D., has joined as the company’s Chairman of the Executive Advisory Board. Under Dr. Dreismann’s leadership as Chief Executive Officer of Roche Molecular Systems, Roche became the global leader in molecular diagnostics by a significant expansion of their portfolio of molecular tests and respective instrumentation. Prior to his appointment as Chief Executive Officer of Roche Molecular Systems, Dr. Dreismann held several other senior positions within Roche, including head of Global Business Development for Roche Diagnostics, Business Unit Europe Manager for PCR, head of Business Unit for Microbiology, as well as R&D positions in microbiology and infectious diseases and the head of manufacturing for infectious disease diagnostics.
MyDx CEO Daniel Yazbeck commented, “Dr. Dreismann is a top industry expert in the field of molecular and medical diagnostics. He has a proven track-record of leadership in the development, commercialization and adoption of diagnostics, and brings valuable real-world experience as we continue to develop our advance our smart devices and data monetization strategies in 2018.”
“Our focus will continue to be getting more of the MyDx diagnostic tools into consumers’ hands,” continued Yazbeck. “Dr. Dreismann, throughout his impressive career and consistent successful track record, has developed numerous domestic and international industry contacts which we believe will open doors for our company. We are very pleased to welcome Dr. Dreismann to MyDx and look forward to his active participation and contribution to our success.”
Dr. Dreismann added, “After having spent time with Mr. Yazbeck and learning more about his vision for MyDx as a leader in science based cannabis health technology, I am pleased to be a part of the team that has developed the first consumer diagnostic that will bring true innovation to personalized medicine. It is my intent to be an active member of the Advisory Board and as I develop a deeper understanding to become even more active with the Company. I intend to bring my experience and contacts, which I believe can create real opportunities for our business as we develop products and seek licensing partners for our technologies.”